Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis (476 views)
Scand J Rheumatol (ISSN: 0300-9742), 2008 May; 37(3): 225-229.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.345, 5-year impact factor: 2.455
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-45549109228&partnerID=40&md5=852d3bd9b96f832855dd67049b0ef53b
Keywords: Interleukin 6, Osteoclast Differentiation Factor, Tnfsf11 Protein, Human, Alkaline Phosphatase Bone Isoenzyme, Colchicine, Nonsteroid Antiinflammatory Agent, Technetium 99m, Adolescent, Article, Blood, Case Report, Osteoarthropathy, Radiography, Scintiscanning, Adult, Anamnesis, Bone Scintiscanning, Bone Turnover, Capillaroscopy, Clinical Feature, Hormone Blood Level, Nuclear Magnetic Resonance Imaging, Osteolysis, Physical Examination, Primary Pachydermoperiostosis, Priority Journal, Primary Hypertrophic, Rank Ligand,
Affiliations:
*** IBB - CNR ***
Department of Clinical and Experimental Medicine, 'Federico II' University Medical School, Naples, Italy
Paediatric Endocrinology Unit, A.O.R.N. 'G. Rummo', Benevento, Italy
Department of Biomorphological and Functional Science, Department of Diagnostic Imaging and Radiotherapy, 'Federico II' University Medical School, Naples, Italy
National Research Council (CNR) Biostructures and Bioimaging Institute, 'Federico II' University Medical School, Naples, Italy
Medical Genetics Unit, A.O.R.N. 'G. Rummo', Benevento, Italy
References:
Castori, M., Sinibaldi, L., Mingarelli, R., Lachman, R.S., Rimoin, D.L., Dallapiccola, B., Pachydermoperiostosis: An update (2005) Clin Gen, 68, pp. 477-48
Auger, M., Stavrianeas, N., Pachydermoperiostosis (2004) Orphanet encyclopedia, , www.orpha.net, Available from:, accessed December 2006
White, M.P., Hereditary metabolic and dysplastic skeletal disorders (2002) Disorders of bone and mineral metabolism, pp. 937-985. , Coe FL, Favus MJ, editors, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins
Jajic, Z., Jajic, I., Nemcic, T., Primary hypertrophic osteoarthropathy: Clinical, radiologic, and scintigraphic characteristics (2001) Arch Med Res, 32, pp. 136-142
Jajic, I., Jajic, Z., Grazio, S., Minor but important symptoms and signs in primary hypertrophic osteoarthropathy (2001) Clin Exp Rheumatol, 19, pp. 357-358
Hughes, H.E., McAlpine, P.J., Cox, D.W., Philipps, S., An autosomal dominant syndrome with 'acromegaloid' features and thickened oral mucosa (1985) J Med Genet, 22, pp. 119-125
Pichler, G., Eber, E., Thalhammer, G., Muntean, W., Zach, M.S., Arthralgia and digital clubbing in a child: Hypertrophic osteoarthropathy with inflammatory pseudotumour of the lung (2004) Scand J Rheumatol, 33, pp. 189-191
Oikarinen, A., Palatsi, R., Kylmaniemi, M., Keski-Oja, J., Risteli, J., Kallioinen, M., Pachydermoperiostosis: Analysis of the connective tissue abnormality in one family (1994) J Am Acad Dermatol, 31, pp. 947-953
Silveri, F., De Angelis, R., Argentati, F., Brecciaroli, D., Muti, S., Cervini, C., Hypertrophic osteoarthropathy: Endothelium and platelet function (1996) Clin Rheumatol, 15, pp. 435-439
Silveira, L.H., Martinez-Lavin, M., Pineda, C., Fonseca, M.C., Navarro, C., Nava, A., Vascular endothelial growth factor and hypertrophic osteoarthropathy (2000) Clin Exp Rheumatol, 18, pp. 57-62
Matucci-Cerinic, M., Martinez-Lavin, M., Rojo, F., Fonseca, C., Kahaleh, B.M., von Willebrand factor antigen in hypertrophic osteoarthropathy (1992) J Rheumatol, 19, pp. 765-767
Fam, A.G., Chin-Sang, H., Ramsay, C.A., Pachydermoperiostosis: Scintigraphic, thermographic, plethysmographic, and capillaroscopic observations (1983) Ann Rheum Dis, 42, pp. 98-102
Kallen, K.J., The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases (2002) Biochim Biophys Acta, 1592, pp. 323-334
Jostock, T., Mullberg, J., Ozbek, S., Atreya, R., Blinn, G., Voltz, N., Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses (2001) Eur J Biochem, 268, pp. 160-167
Boyle, W.J., Simonet, W.S., Lacey, D.L., Osteoclast differentiation and activation (2003) Nature, 423, pp. 337-342
Franchimont, N., Wertz, S., Malaise, M., Interleukin-6: An osteotropic factor influencing bone formation? (2005) Bone, 37, pp. 601-606
Jones, S.A., Rose-John, S., The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6R/IL-6 complex (2002) Biochim Biophys Acta, 1592, pp. 251-263
Kwan Tat, S., Padrines, M., Theoleyre, S., Heymann, D., Fortun, Y., IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology (2004) Cytokine Growth Factor Rev, 15, pp. 49-60
Mossetti, G., Rendina, D., De Filippo, G., Viceconti, R., Di Domenico, G., Cioffi, M., Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: Relationship to risedronate treatment (2005) Bone, 36, pp. 549-554
Angelo, L.S., Kurzrock, R., Vascular endothelial growth factor and its relationship to inflammatory mediators (2007) Clin Cancer Res, 13, pp. 2825-2830
Knudsen, L.S., Ostergaard, M., Baslund, B., Narvestad, E., Petersen, J., Nielsen, H.J., Plasma IL-6, plasma VEGF, and serum YKL-40: Relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate (2006) Scand J Rheumatol, 35, pp. 489-491
Brandi, M.L., Collin-Osdoby, P., Vascular biology and the skeleton (2006) J Bone Miner Res, 21, pp. 183-192
Roodman, G.D., Treatment strategies for bone disease (2007) Bone Marrow Transplant, 4, pp. 1139-1146
White, M. P., Hereditary metabolic and dysplastic skeletal disorders (2002) Disorders of bone and mineral metabolism, pp. 937-985. , Coe FL, Favus MJ, editors, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins
Hughes, H. E., McAlpine, P. J., Cox, D. W., Philipps, S., An autosomal dominant syndrome with 'Acromegaloid' features and thickened oral mucosa (1985) J Med Genet, 22, pp. 119-125
Silveira, L. H., Martinez-Lavin, M., Pineda, C., Fonseca, M. C., Navarro, C., Nava, A., Vascular endothelial growth factor and hypertrophic osteoarthropathy (2000) Clin Exp Rheumatol, 18, pp. 57-62
Fam, A. G., Chin-Sang, H., Ramsay, C. A., Pachydermoperiostosis: Scintigraphic, thermographic, plethysmographic, and capillaroscopic observations (1983) Ann Rheum Dis, 42, pp. 98-102
Kallen, K. J., The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases (2002) Biochim Biophys Acta, 1592, pp. 323-334
Boyle, W. J., Simonet, W. S., Lacey, D. L., Osteoclast differentiation and activation (2003) Nature, 423, pp. 337-342
Jones, S. A., Rose-John, S., The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6R/IL-6 complex (2002) Biochim Biophys Acta, 1592, pp. 251-263
Angelo, L. S., Kurzrock, R., Vascular endothelial growth factor and its relationship to inflammatory mediators (2007) Clin Cancer Res, 13, pp. 2825-2830
Knudsen, L. S., Ostergaard, M., Baslund, B., Narvestad, E., Petersen, J., Nielsen, H. J., Plasma IL-6, plasma VEGF, and serum YKL-40: Relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate (2006) Scand J Rheumatol, 35, pp. 489-491
Brandi, M. L., Collin-Osdoby, P., Vascular biology and the skeleton (2006) J Bone Miner Res, 21, pp. 183-192
Roodman, G. D., Treatment strategies for bone disease (2007) Bone Marrow Transplant, 4, pp. 1139-1146
Scand J Rheumatol (ISSN: 0300-9742), 2008 May; 37(3): 225-229.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.345, 5-year impact factor: 2.455
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-45549109228&partnerID=40&md5=852d3bd9b96f832855dd67049b0ef53b
Keywords: Interleukin 6, Osteoclast Differentiation Factor, Tnfsf11 Protein, Human, Alkaline Phosphatase Bone Isoenzyme, Colchicine, Nonsteroid Antiinflammatory Agent, Technetium 99m, Adolescent, Article, Blood, Case Report, Osteoarthropathy, Radiography, Scintiscanning, Adult, Anamnesis, Bone Scintiscanning, Bone Turnover, Capillaroscopy, Clinical Feature, Hormone Blood Level, Nuclear Magnetic Resonance Imaging, Osteolysis, Physical Examination, Primary Pachydermoperiostosis, Priority Journal, Primary Hypertrophic, Rank Ligand,
Affiliations:
*** IBB - CNR ***
Department of Clinical and Experimental Medicine, 'Federico II' University Medical School, Naples, Italy
Paediatric Endocrinology Unit, A.O.R.N. 'G. Rummo', Benevento, Italy
Department of Biomorphological and Functional Science, Department of Diagnostic Imaging and Radiotherapy, 'Federico II' University Medical School, Naples, Italy
National Research Council (CNR) Biostructures and Bioimaging Institute, 'Federico II' University Medical School, Naples, Italy
Medical Genetics Unit, A.O.R.N. 'G. Rummo', Benevento, Italy
References:
Castori, M., Sinibaldi, L., Mingarelli, R., Lachman, R.S., Rimoin, D.L., Dallapiccola, B., Pachydermoperiostosis: An update (2005) Clin Gen, 68, pp. 477-48
Auger, M., Stavrianeas, N., Pachydermoperiostosis (2004) Orphanet encyclopedia, , www.orpha.net, Available from:, accessed December 2006
White, M.P., Hereditary metabolic and dysplastic skeletal disorders (2002) Disorders of bone and mineral metabolism, pp. 937-985. , Coe FL, Favus MJ, editors, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins
Jajic, Z., Jajic, I., Nemcic, T., Primary hypertrophic osteoarthropathy: Clinical, radiologic, and scintigraphic characteristics (2001) Arch Med Res, 32, pp. 136-142
Jajic, I., Jajic, Z., Grazio, S., Minor but important symptoms and signs in primary hypertrophic osteoarthropathy (2001) Clin Exp Rheumatol, 19, pp. 357-358
Hughes, H.E., McAlpine, P.J., Cox, D.W., Philipps, S., An autosomal dominant syndrome with 'acromegaloid' features and thickened oral mucosa (1985) J Med Genet, 22, pp. 119-125
Pichler, G., Eber, E., Thalhammer, G., Muntean, W., Zach, M.S., Arthralgia and digital clubbing in a child: Hypertrophic osteoarthropathy with inflammatory pseudotumour of the lung (2004) Scand J Rheumatol, 33, pp. 189-191
Oikarinen, A., Palatsi, R., Kylmaniemi, M., Keski-Oja, J., Risteli, J., Kallioinen, M., Pachydermoperiostosis: Analysis of the connective tissue abnormality in one family (1994) J Am Acad Dermatol, 31, pp. 947-953
Silveri, F., De Angelis, R., Argentati, F., Brecciaroli, D., Muti, S., Cervini, C., Hypertrophic osteoarthropathy: Endothelium and platelet function (1996) Clin Rheumatol, 15, pp. 435-439
Silveira, L.H., Martinez-Lavin, M., Pineda, C., Fonseca, M.C., Navarro, C., Nava, A., Vascular endothelial growth factor and hypertrophic osteoarthropathy (2000) Clin Exp Rheumatol, 18, pp. 57-62
Matucci-Cerinic, M., Martinez-Lavin, M., Rojo, F., Fonseca, C., Kahaleh, B.M., von Willebrand factor antigen in hypertrophic osteoarthropathy (1992) J Rheumatol, 19, pp. 765-767
Fam, A.G., Chin-Sang, H., Ramsay, C.A., Pachydermoperiostosis: Scintigraphic, thermographic, plethysmographic, and capillaroscopic observations (1983) Ann Rheum Dis, 42, pp. 98-102
Kallen, K.J., The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases (2002) Biochim Biophys Acta, 1592, pp. 323-334
Jostock, T., Mullberg, J., Ozbek, S., Atreya, R., Blinn, G., Voltz, N., Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses (2001) Eur J Biochem, 268, pp. 160-167
Boyle, W.J., Simonet, W.S., Lacey, D.L., Osteoclast differentiation and activation (2003) Nature, 423, pp. 337-342
Franchimont, N., Wertz, S., Malaise, M., Interleukin-6: An osteotropic factor influencing bone formation? (2005) Bone, 37, pp. 601-606
Jones, S.A., Rose-John, S., The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6R/IL-6 complex (2002) Biochim Biophys Acta, 1592, pp. 251-263
Kwan Tat, S., Padrines, M., Theoleyre, S., Heymann, D., Fortun, Y., IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology (2004) Cytokine Growth Factor Rev, 15, pp. 49-60
Mossetti, G., Rendina, D., De Filippo, G., Viceconti, R., Di Domenico, G., Cioffi, M., Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: Relationship to risedronate treatment (2005) Bone, 36, pp. 549-554
Angelo, L.S., Kurzrock, R., Vascular endothelial growth factor and its relationship to inflammatory mediators (2007) Clin Cancer Res, 13, pp. 2825-2830
Knudsen, L.S., Ostergaard, M., Baslund, B., Narvestad, E., Petersen, J., Nielsen, H.J., Plasma IL-6, plasma VEGF, and serum YKL-40: Relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate (2006) Scand J Rheumatol, 35, pp. 489-491
Brandi, M.L., Collin-Osdoby, P., Vascular biology and the skeleton (2006) J Bone Miner Res, 21, pp. 183-192
Roodman, G.D., Treatment strategies for bone disease (2007) Bone Marrow Transplant, 4, pp. 1139-1146
White, M. P., Hereditary metabolic and dysplastic skeletal disorders (2002) Disorders of bone and mineral metabolism, pp. 937-985. , Coe FL, Favus MJ, editors, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins
Hughes, H. E., McAlpine, P. J., Cox, D. W., Philipps, S., An autosomal dominant syndrome with 'Acromegaloid' features and thickened oral mucosa (1985) J Med Genet, 22, pp. 119-125
Silveira, L. H., Martinez-Lavin, M., Pineda, C., Fonseca, M. C., Navarro, C., Nava, A., Vascular endothelial growth factor and hypertrophic osteoarthropathy (2000) Clin Exp Rheumatol, 18, pp. 57-62
Fam, A. G., Chin-Sang, H., Ramsay, C. A., Pachydermoperiostosis: Scintigraphic, thermographic, plethysmographic, and capillaroscopic observations (1983) Ann Rheum Dis, 42, pp. 98-102
Kallen, K. J., The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases (2002) Biochim Biophys Acta, 1592, pp. 323-334
Boyle, W. J., Simonet, W. S., Lacey, D. L., Osteoclast differentiation and activation (2003) Nature, 423, pp. 337-342
Jones, S. A., Rose-John, S., The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6R/IL-6 complex (2002) Biochim Biophys Acta, 1592, pp. 251-263
Angelo, L. S., Kurzrock, R., Vascular endothelial growth factor and its relationship to inflammatory mediators (2007) Clin Cancer Res, 13, pp. 2825-2830
Knudsen, L. S., Ostergaard, M., Baslund, B., Narvestad, E., Petersen, J., Nielsen, H. J., Plasma IL-6, plasma VEGF, and serum YKL-40: Relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate (2006) Scand J Rheumatol, 35, pp. 489-491
Brandi, M. L., Collin-Osdoby, P., Vascular biology and the skeleton (2006) J Bone Miner Res, 21, pp. 183-192
Roodman, G. D., Treatment strategies for bone disease (2007) Bone Marrow Transplant, 4, pp. 1139-1146
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis
Primary pachydermoperiostosis (PDP) is a rare syndrome, characterized by digital clubbing, periostosis, and pachydermia. We have evaluated biochemical bone turnover markers, including components of interleukin-6 (IL-6) and osteoprotegerin/receptor activator of nuclear factor (NF)-κB ligand (OPG/RANKL) systems, in an 18-year-old man affected by primary PDP. The acute phase of the disease was characterized in our patient by high serum levels of IL-6 and RANKL. The observed high serum levels of these parameters are associated with increased values in markers of bone resorption (degradation products of C-terminal telopeptides of type-I collagen and urinary hydroxyproline/creatinine ratio) and reduced serum levels of bone alkaline phosphatase, a marker of bone formation. Serum levels of osteotrophic hormones were in the normal range. Our data suggest that, despite the radiographic findings, the acute phase of primary PDP is characterized by increased bone resorption, probably mediated by IL-6 and RANKL. © 2008 Taylor & Francis on license from Scandinavian Rheumatology Research Foundation.
Primary pachydermoperiostosis (PDP) is a rare syndrome, characterized by digital clubbing, periostosis, and pachydermia. We have evaluated biochemical bone turnover markers, including components of interleukin-6 (IL-6) and osteoprotegerin/receptor activator of nuclear factor (NF)-κB ligand (OPG/RANKL) systems, in an 18-year-old man affected by primary PDP. The acute phase of the disease was characterized in our patient by high serum levels of IL-6 and RANKL. The observed high serum levels of these parameters are associated with increased values in markers of bone resorption (degradation products of C-terminal telopeptides of type-I collagen and urinary hydroxyproline/creatinine ratio) and reduced serum levels of bone alkaline phosphatase, a marker of bone formation. Serum levels of osteotrophic hormones were in the normal range. Our data suggest that, despite the radiographic findings, the acute phase of primary PDP is characterized by increased bone resorption, probably mediated by IL-6 and RANKL. © 2008 Taylor & Francis on license from Scandinavian Rheumatology Research Foundation.
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis
No results. |
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis
Other filter: ([btitle,keywords] "Interleukin 6" OR [b ...
Cimmino I, Prisco F, Orso S, Agognon AL, Liguoro P, De Biase D, Doti N, Ruvo M, Paciello O, Beguinot F, Formisano P, Oriente F
* Interleukin 6 reduces vascular smooth muscle cell apoptosis via Prep1 and is associated with aging (10 views)
Faseb J (ISSN: 0892-6638linking), 2021 Nov; 35(11): e21989-N/D.
Impact Factor: 5.191
View Export to BibTeX Export to EndNote
Lanzillo R, Carbone F, Quarantelli M, Bruzzese D, Carotenuto A, De RosaV, Colamatteo A, Micillo T, De Luca Picione C, Saccà F, De Rosa A, Moccia M, Brescia Morra V, Matarese G
* Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a (383 views)
Clin Immunol (ISSN: 1521-6616), 2017 Oct; 183: 249-253.
Impact Factor: 3.557
View Export to BibTeX Export to EndNote
Dolga AM, Letsche T, Gold M, Doti N, Bacher M, Chiamvimonvat N, Dodel R, Culmsee C
* Activation of KCNN3/SK3/K(Ca)2. 3 channels attenuates enhanced calcium influx and inflammatory cytokine production in activated microglia (553 views)
Glia (ISSN: 1098-1136), 2012 Dec; 60(12): 2050-2064.
Impact Factor: 5.466
View Export to BibTeX Export to EndNote
Galdiero S, Falanga A, Cantisani M, Tarallo R, della Pepa ME, D'Oriano V, Galdiero M
* Microbe-Host Interactions: Structure and Role of Gram-Negative Bacterial Porins (629 views)
Curr Protein Pept Sci (ISSN: 1389-2037, 1389-2037linking), 2012 Dec; 13(8): 843-854.
Impact Factor: 2.326
View Export to BibTeX Export to EndNote
Cantisani M, Vitiello M, Falanga A, Finamore E, Galdiero M, Galdiero S
* Peptides complementary to the active loop of porin P2 from Haemophilus influenzae modulate its activity (510 views)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1178-2013electronic), 2012; 7: 2361-2371.
Impact Factor: 3.463
View Export to BibTeX Export to EndNote
Galdiero S, Vitiello M, Amodeo P, D'Isanto M, Cantisani M, Pedone C, Galdiero M
* Structural requirements for proinflammatory activity of porin P2 loop 7 from Haemophilus influenzae (514 views)
Biochemistry (ISSN: 0006-2960, 1520-4995, 1520-4995electronic), 2006 Apr 11; 45(14): 4491-4501.
Impact Factor: 3.633
View Export to BibTeX Export to EndNote
Borgatti M, Finotti A, Romanelli A, Saviano M, Bianchi N, Lampronti I, Lambertini E, Penolazzi L, Nastruzzi C, Mischiati C, Piva R, Pedone C, Gambari R
* Peptide nucleic acids (PNA)-DNA chimeras targeting transcription factors as a tool to modify gene expression (478 views)
Curr Drug Targets (ISSN: 1389-4501), 2004 Nov; 5(8): 735-744.
Impact Factor: 4.104
View Export to BibTeX Export to EndNote
Levchenko A, Mehta B, Spengler BA, Narkar A, Fonti R, Biedler JL, Tsuruo T, Larson SM
Measurement of P-glycoprotein expression in multidrug-resistant human neuroblastoma cell lines using self-competitive binding assay (283 views)
Anal Biochem (ISSN: 0003-2697, 1096-0309electronic, 0003-2697linking), 1996 May 1; 236(2): 338-343.
Impact Factor: 2.017
View Export to BibTeX Export to EndNote
* Interleukin 6 reduces vascular smooth muscle cell apoptosis via Prep1 and is associated with aging (10 views)
Faseb J (ISSN: 0892-6638linking), 2021 Nov; 35(11): e21989-N/D.
Impact Factor: 5.191
View Export to BibTeX Export to EndNote
Lanzillo R, Carbone F, Quarantelli M, Bruzzese D, Carotenuto A, De RosaV, Colamatteo A, Micillo T, De Luca Picione C, Saccà F, De Rosa A, Moccia M, Brescia Morra V, Matarese G
* Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a (383 views)
Clin Immunol (ISSN: 1521-6616), 2017 Oct; 183: 249-253.
Impact Factor: 3.557
View Export to BibTeX Export to EndNote
Dolga AM, Letsche T, Gold M, Doti N, Bacher M, Chiamvimonvat N, Dodel R, Culmsee C
* Activation of KCNN3/SK3/K(Ca)2. 3 channels attenuates enhanced calcium influx and inflammatory cytokine production in activated microglia (553 views)
Glia (ISSN: 1098-1136), 2012 Dec; 60(12): 2050-2064.
Impact Factor: 5.466
View Export to BibTeX Export to EndNote
Galdiero S, Falanga A, Cantisani M, Tarallo R, della Pepa ME, D'Oriano V, Galdiero M
* Microbe-Host Interactions: Structure and Role of Gram-Negative Bacterial Porins (629 views)
Curr Protein Pept Sci (ISSN: 1389-2037, 1389-2037linking), 2012 Dec; 13(8): 843-854.
Impact Factor: 2.326
View Export to BibTeX Export to EndNote
Cantisani M, Vitiello M, Falanga A, Finamore E, Galdiero M, Galdiero S
* Peptides complementary to the active loop of porin P2 from Haemophilus influenzae modulate its activity (510 views)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1178-2013electronic), 2012; 7: 2361-2371.
Impact Factor: 3.463
View Export to BibTeX Export to EndNote
Galdiero S, Vitiello M, Amodeo P, D'Isanto M, Cantisani M, Pedone C, Galdiero M
* Structural requirements for proinflammatory activity of porin P2 loop 7 from Haemophilus influenzae (514 views)
Biochemistry (ISSN: 0006-2960, 1520-4995, 1520-4995electronic), 2006 Apr 11; 45(14): 4491-4501.
Impact Factor: 3.633
View Export to BibTeX Export to EndNote
Borgatti M, Finotti A, Romanelli A, Saviano M, Bianchi N, Lampronti I, Lambertini E, Penolazzi L, Nastruzzi C, Mischiati C, Piva R, Pedone C, Gambari R
* Peptide nucleic acids (PNA)-DNA chimeras targeting transcription factors as a tool to modify gene expression (478 views)
Curr Drug Targets (ISSN: 1389-4501), 2004 Nov; 5(8): 735-744.
Impact Factor: 4.104
View Export to BibTeX Export to EndNote
Levchenko A, Mehta B, Spengler BA, Narkar A, Fonti R, Biedler JL, Tsuruo T, Larson SM
Measurement of P-glycoprotein expression in multidrug-resistant human neuroblastoma cell lines using self-competitive binding assay (283 views)
Anal Biochem (ISSN: 0003-2697, 1096-0309electronic, 0003-2697linking), 1996 May 1; 236(2): 338-343.
Impact Factor: 2.017
View Export to BibTeX Export to EndNote
8 Records (8 excluding Abstracts).
Total impact factor: 29.757 (29.757 excluding Abstracts).
Total 5 year impact factor: 32.52 (32.52 excluding Abstracts).
Total impact factor: 29.757 (29.757 excluding Abstracts).
Total 5 year impact factor: 32.52 (32.52 excluding Abstracts).
476 views. Last view on Tuesday 21 March 2023, 2:56:40
ibb.cnr.it
